Articles with keyword survival

• Overall survival of patients with hepatocellular carcinoma of different etiologies?

  V.V. Petkau, E.N. Bessonova, V.V. Breder, Е.А. Kiselev, К.Е. Kiseleva

  hepatocellular carcinoma, overall survival, prognostic factors, etiology.

• MSI-H cancer – what has happened in the last year?

  V.A. Chubenko

  microsatellite instability, overall survival, clinical trials.

• 2016: advances in medical oncology

  V.A. Chubenko

  immunotherapy, target therapy, overall survival, treatment guidelines

• MEDICAL TREATMENT OF TUMORS: WHAT NEED TO KNOW A PRAC TICAL ONCOLOGIST

  V.A. Chubenko

  chemotherapy, immunotherapy, target therapy, overall survival, treatment guidelines.

• Combinations of immunotherapy and other drugs

  V.A. Chubenko

  Target therapy, chemotherapy, check-point inhibitors, overall survival.

• Palliative resections in metastatic colorectal cancer: to whom and when? literature review

  I.I. Aliev, D.A. Ivlev, A.Y. Berdinskikh, E.Y. Klimov.

  colorectal cancer, hepatic metastases, palliative surgery, overall survival.

• Rationale for systemic therapy administration in clinically localised tumors

  N.M. Volkov

  localized tumors, systemic therapy, micrometastases, disseminated tumor cells, survival.

• Tumour board for decision making

  V.A. Chubenko

  tumour board, multidisciplinary group (MTD), quality of the treatment, overall survival.

• PROGNOSTIC SIGNIFICANCE OF STEM CELLS TUMORS AND ALK EXPRESSION IN PATIENTS WITH PRIMARY SKINMELANOMA

  K.S. Titov, M.A. Baryshnikova, A.M. Kazakov, D.A. Khochenkov, E.P. Larionova, D.A. Ryabchikov

  tumor stem cell, ABCB5, CD133, ALK, lymphoid infiltration, 2-year survival.

• Overdiagnosis of thyroid cancer

  D.G. Zaridze, I.S. Stilidi, A.D. Kaprin, D.M. Maksimovich

  thyroid cancer, incidence, mortality, trends, latent cancer, non-invasive follicular neoplasia, ultrasound screening, survival, overdiagnosis

• History of cancer hormonothe

  N.K. Abduloeva, M.V. Scriabin, О.А. Skripko, S.K. Kaitova, R.A. Ryandjina, K.N. Kazakova, V.M. Moiseenko

  breast cancer, epidemiology, risk factors, classification, diagnosis, prognosis, marker, treatment, Lobular carcinoma in situ ((DCIS), time to progression (TTP), complete regression, partial regression, metastatic breast cancer (MBC), median progression-free survival (PFS), overall response, LH-RH agonists and antagonists, receptor estrogen, LH-releasing hormone, Gonadotropin-releasing-hormone-receptor antagonists, overall survival, prostate cancer, Castration-resistant prostate cancer (CRPC), receptor androgens, prostate-specific antigen (PSA)